Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanisms

Molecular Pharmacology

Volumn 84, Issue 6, 2013, Pages 911-924

  Merlot, Angelica M ^a   Pantarat, Namfon ^a   Menezes, Sharleen V ^a   Sahni, Sumit ^a   Richardson, Des R ^a   Kalinowski, Danuta S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZOYLPYRIDINE 4 ETHYL 3 THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; CARBON 14; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; IODINE 125; IRON 59; PYRIDOXAL ISONICOTINOYL HYDRAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOCYTOSIS; EXOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MEMBRANE; CHELATING AGENTS; COORDINATION COMPLEXES; COPPER; ENDOCYTOSIS; FEMALE; HETEROGRAFTS; HUMANS; IRON; ISONIAZID; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRIDOXAL; TEMPERATURE; THIOSEMICARBAZONES;

EID: 84888867465     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088393     Document Type: Article

References (60)

1. Baker E, Richardson D, Gross S, and Ponka P (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:492-501.
2. Baker E, Vitolo ML, and Webb J (1985) Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 34: 3011-3017.
3. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Ménard S, and Pratesi G (2004) Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 40:1275-1281.
4. Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS, and Richardson DR (2009) Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem 52:407-415.
5. Buss JL, Torti FM, and Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021-1034.
6. Chao J, Synold TW, Morgan RJ, Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, and Stoller RG et al. (2012) A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol 69:835-843.
7. Chaston TB, Lovejoy DB, Watts RN, and Richardson DR (2003) Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9: 402-414.
8. Chung MC-M (1984) Structure and function of transferrin. Biochem Educ 12: 146-154.
9. Ciechanover A, Schwartz AL, and Lodish HF (1983) The asialoglycoprotein receptor internalizes and recycles independently of the transferrin and insulin receptors. Cell 32:267-275.
10. Deutsch JC, Elwood PC, Portillo RM, Macey MG, and Kolhouse JF (1989) Role of the membrane-associated folate binding protein (folate receptor) in methotrexate transport by human KB cells. Arch Biochem Biophys 274:327-337.
11. Duffy KJ, Shaw AN, Delorme E, Dillon SB, Erickson-Miller C, Giampa L, Huang Y, Keenan RM, Lamb P, and Liu N et al. (2002) Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 45:3573-3575.
12. Edward JT, Ponka P, and Richardson DR (1995) Partition coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy. Biometals 8:207-217.
13. Elford HL, Freese M, Passamani E, and Morris HP (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245:5228-5233.
14. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674.
15. Harding C, Heuser J, and Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97: 329-339.
16. Henderson GB and Zevely EM (1984) Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J Biol Chem 259:1526-1531.
17. Hsieh HS and Frieden E (1975) Evidence for ceruloplasmin as a copper transport protein. Biochem Biophys Res Commun 67:1326-1331.
18. Iacopetta BJ and Morgan EH (1983) The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. J Biol Chem 258:9108-9115.
19. Ishida S, Lee J, Thiele DJ, and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302.
20. Jansson PJ, Sharpe PC, Bernhardt PV, and Richardson DR (2010) Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem 53:5759-5769.
21. Kalinowski DS and Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583.
22. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, and Richardson DR (2007) Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 50:3716-3729.
23. Kovacevic Z, Chikhani S, Lovejoy DB, and Richardson DR (2011) Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol 80:598-609.
24. Kovaríková P, Klimes J, Stirba M, Popelová O, Mokrý M, Gersl V, and Ponka P (2005) Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci 28:1300-1306.
25. Le NT and Richardson DR (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104:2967-2975.
26. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, and Mo YY et al. (2012) N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 4:93-108.
27. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P, and Richardson DR (2011) Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res 71: 5871-5880.
28. Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, Basha MT, Sharpe PC, Jansson PJ, and Kalinowski DS et al. (2012) Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem 55:7230-7244.
29. McFarlane AS (1958) Efficient trace-labelling of proteins with iodine. Nature 182:53.
30. Merlot AM, Kalinowski DS, and Richardson DR (2013) Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal 18:973-1006.
31. Merlot AM, Pantarat N, Lovejoy DB, Kalinowski DS, and Richardson DR (2010) Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer. Mol Pharmacol 78:675-684.
32. Moore PA (1981) Preparation of whole blood for liquid scintillation counting. Clin Chem 27:609-611.
33. Morgan EH (1981) Transferrin, biochemistry, physiology, and clinical significance. Mol Aspects Med 4:1-123.
34. Morgan EH and Baker E (1969) The effect of metabolic inhibitors on transferrin and iron uptake and transferrin release from reticulocytes. Biochim Biophys Acta 184: 442-454.
35. Mulford CA and Lodish HF (1988) Endocytosis of the transferrin receptor is altered during differentiation of murine erythroleukemic cells. J Biol Chem 263: 5455-5461.
36. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, and Pattanapanyasat K (2009) Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 84:170-176.
37. Osman S, Luthra SK, Brady F, Hume SP, Brown G, Harte RJ, Matthews JC, Denny WA, Baguley BC, and Jones T et al. (1997) Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4- carboxamide in rats and humans prior to phase I clinical trials. Cancer Res 57:2172-2180.
38. Pinnix ZK, Miller LD, Wang W, D' Agostino R, Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, and Di X et al. (2010) Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2 :43ra56.
39. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, and Hider RC (1988) Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 72: 1497-1503.
40. Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J, Jr, and Mir LM (1999) Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57: 45-56.
41. Qian ZM and Morgan EH (1991) Effect of metabolic inhibitors on uptake of non-transferrin-bound iron by reticulocytes. Biochim Biophys Acta 1073:456-462.
42. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, and Shacter EB (2009) The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res 69:948-957.
43. Richardson D, Ponka P, and Baker E (1994) The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54:685-689.
44. Richardson DR (1997) Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim Biophys Acta 1320:45-57.
45. Richardson DR and Baker E (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim Biophys Acta 1053:1-12.
46. Richardson DR, Kalinowski DS, Richardson V, Sharpe PC, Lovejoy DB, Islam M, and Bernhardt PV (2009) 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem 52:1459-1470.
47. Richardson DR and Ponka P (1994) The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124:660-671.
48. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, and Bernhardt PV (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49:6510-6521.
49. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
50. Seymour GJ, Walsh MD, Lavin MF, Strutton G, and Gardiner RA (1987) Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 15: 341-344.
51. Soyer HP, Smolle J, Torne R, and Kerl H (1987) Transferrin receptor expression in normal skin and in various cutaneous tumors. J Cutan Pathol 14:1-5.
52. Stariat J, Kovaříková P, Kučera R, Klimeš J, Kalinowski DS, Richardson DR, and Ketola RA (2013) Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography- quadrupole- time-of-flight mass spectrometry. Anal Bioanal Chem 405:1651-1661.
53. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, Ecker GF, Faller B, Fischer H, and Gerebtzoff G et al. (2010) Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9 :597-614.
54. Takeda E and Weber G (1981) Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 28:1007-1014.
55. Tian J, Peehl DM, Zheng W, and Knox SJ (2010) Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett 298:231-237.
56. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, and Sznol M (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3- aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22:1553-1563.
57. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906.
58. Yu Y, Suryo Rahmanto Y, Hawkins CL, and Richardson DR (2011) The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol 79:921-931.
59. Yu Y, Suryo Rahmanto Y, and Richardson DR (2012) Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol 165:148-166.
60. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458.